Norbert Galldiks
Overview
Explore the profile of Norbert Galldiks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
245
Citations
5550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedrich M, Werner J, Steinbach J, Sabel M, Herrlinger U, Piroth M, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf023.
PMID: 40084168
Background: Amino acid PET using the tracer -(2-[F]fluoroethyl)-l-tyrosine (FET) is one of the most reliable imaging methods for detecting glioma recurrence. Here, we hypothesized that functional MR connectivity between the...
2.
Langen K, Stoffels G, Filss C, Kocher M, Lerche C, Sabel M, et al.
J Nucl Med
. 2025 Jan;
66(2):187-193.
PMID: 39819686
One of the most common clinical indications for amino acid PET using the tracer -(2-[F]-fluoroethyl)-l-tyrosine (F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A...
3.
Kotecha R, Akdemir E, Kutuk T, Ilgin C, Ahluwalia M, Bi W, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39807850
Background: Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of...
4.
Ceccon G, Werner J, Ruge M, Goldbrunner R, Celik E, Baues C, et al.
Clin Nucl Med
. 2025 Jan;
50(4):307-315.
PMID: 39806562
Purpose: Especially in Europe, amino acid PET is increasingly integrated into multidisciplinary neuro-oncological tumor boards (MNTBs) to overcome diagnostic uncertainties such as treatment-related changes. We evaluated the accuracy of MNTB...
5.
Verger A, Tolboom N, Cicone F, Chang S, Furtner J, Galldiks N, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39762634
This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology...
6.
Galldiks N, Werner J, Stetter I, Puhr H, Nakuz T, Stoffels G, et al.
Neurooncol Adv
. 2024 Dec;
6(1):vdae210.
PMID: 39737092
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI...
7.
Bakas S, Vollmuth P, Galldiks N, Booth T, Aerts H, Bi W, et al.
Lancet Oncol
. 2024 Oct;
25(11):e589-e601.
PMID: 39481415
Technological advancements have enabled the extended investigation, development, and application of computational approaches in various domains, including health care. A burgeoning number of diagnostic, predictive, prognostic, and monitoring biomarkers are...
8.
Villanueva-Meyer J, Bakas S, Tiwari P, Lupo J, Calabrese E, Davatzikos C, et al.
Lancet Oncol
. 2024 Oct;
25(11):e581-e588.
PMID: 39481414
The development, application, and benchmarking of artificial intelligence (AI) tools to improve diagnosis, prognostication, and therapy in neuro-oncology are increasing at a rapid pace. This Policy Review provides an overview...
9.
Baumert B, Jaspers J, Keil V, Galldiks N, Izycka-Swieszewska E, Timmermann B, et al.
Radiother Oncol
. 2024 Oct;
202:110594.
PMID: 39454886
Purpose: This guideline will discuss radiotherapeutic management of IDH-mutant grade 2 and grade 3 diffuse glioma, using the latest 2021 WHO (5th) classification of brain tumours focusing on: imaging modalities,...
10.
Albert N, Preusser M, Galldiks N, Ivanidze J
J Nucl Med
. 2024 Oct;
66(1):24-25.
PMID: 39389626
No abstract available.